On 18 February 2026, the European Commission withdrew the marketing authorisation for Xevudy (sotrovimab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, GlaxoSmithKline Trading Services Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Xevudy was granted marketing authorisation in the EU on 17 December 2021 for the treatment of coronavirus disease 2019 (COVID\-19\). The marketing authorisation was initially valid for a 5\-year period.
Therapeutic Indication
Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID\-19\) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID\-19\.
Therapeutic Area (MeSH)
ATC Code
J06BD05
ATC Item
N/A
Pharmacotherapeutic Group
Immune sera and immunoglobulins
Active Substance (Summary)
INN / Common Names
EMA Name
Xevudy
Medicine Name
Xevudy
Aliases
N/ANo risk management plan link.
